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Objectives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of health 
including pharmaceutical sales by improving access to health services. The objective 
of this analysis is to to understand the impact of selected 5 major policy changes 
by MoH to sales of locally manufactured and imported pharmaceutical products in 
the respective periods. MethOds: 132 months sales data with segmented regres-
sion analysis for interrupted time series were used. International reference pricing 
of pharmaceuticals (RF), mandatory reimbursement dossier submission for new 
molecules, new indications and line extensions with medical and economic evalu-
ations (MRDS), auditing for good manufacturing practice (GMP), family physician 
system (FP) and compulsory medical service for physicians (CMS) were selected as 
five major policies that may affect cost, demand and supply of pharmaceuticals. 
The analysis was conducted for total imported pharmaceutical (IP) sales and total 
locally manufactured pharmaceutical (LMP) sales. The Durbin-Watson d statistics 
of SPSS version 20.0 was used as serial correlation. Shift in slope with p< 0.05 was 
considered as statistically significant. Results: The negative effect of RF policy 
change on CS trends was more prominent for IP than LMP sales. However, the shift 
in CS due to other 4 policy changes was lower for IP when compared with LMP 
sales. The differences reached statistical significance level except for CMS policy. 
Although not significant, positive shift of US due to RF policy change was higher for 
LMP than IP sales. There was a decreasing slope of LMP unit sales following MRDS 
and GMP policies but an increasing slope of IP unit sales. cOnclusiOns: Policy 
changes may effect at differently direction and amount the unit and cost sales 
of LMPs and IPs. Cost control mechnism such as RF has a more negative effect on 
imported product as expected.
PHP33
an overvIew of tHe BIosImIlar market In tHe us
Young K.E.1, Rémuzat C.2, Urbinati D.3, Toumi M.4
1Creativ-Ceutical, Milan, Italy, 2Creativ-Ceutical, Paris, France, 3Creativ-Ceutical, Luxembourg, 
Luxembourg, 4University Aix-Marseille, Marseille, France
Objectives: This study intends to provide an overview of the US biosimilar poli-
cies and its impact on the development of the biosimilar market in this coun-
try. MethOds: A literature review was conducted from the US Food and Drug 
Administration (FDA) website, Generics and Biosimilars Initiative (GaBi) web-
sites, Medline® database, and available grey literature. Results: The Biologics 
Price Competition and Innovation Act (2009) established an abbreviated Biologic 
License Application (aBLA) pathway/351 (k) for biosimilars in addition to the 1. 
Non-abbreviated biologic license application (BLA) /351 (a); 2. New Drug Application 
(NDA) /505 (b) (2); or 3. Abbreviated New Drug Application (ANDA). 10 follow-on 
biologics under NDA/ANDA and one under BLA were previously approved. Product 
identity and therapeutic equivalence of some biologics (i. e. Lovenox, Copaxone) led 
to important debates for defining the application pathway. Currently, the FDA has no 
351 (k) approvals. The lack of clear FDA guidance on data requirements for biosimi-
larity in aBLA was a limiting factor for manufacturers to go through aBLA pathway. 
They preferably opted for a classical BLA pathway due to its longer exclusivity period 
and nearly the same amount of data required (i. e. Neutroval). The impact of the 
recently released FDA draft guidance on designing clinical studies for biosimilar-
ity (5/13/14) is yet to be seen but should address issues on proving biosimilarity 
in aBLA. Further debate is anticipated but an increase in applications is expected 
and biosimilars savings are projected at $250 billion by 2024. cOnclusiOns: 
The biosimilars market is still lagging, specifically compared to the EU, with no 
351 (k) approvals despite the US’ leading position in the biopharmaceuticals market. 
However, the US’ high prices for innovative products and history of generic utiliza-
tion can signify a positive market projection after a transition period, as was seen 
in Germany and Sweden. Further, the new FDA guidance by addressing biosimilarity 
issues may ease biosimilar market entry.
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Objectives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of health 
including pharmaceutical sales by improving access to health services. Total phar-
maceutical market reached US $ 8 billion in last 10 years. The objective of this 
analysis is to understand the impact of selected 5 major policy changes by MoH 
on the growth locally manufactured and imported pharmaceutical markets of top 
selling ATC1 phramaceutical group, which was Alimentary and Metabolism (A0) 
with US $ 1.1 billion sales in 2012, in the respective periods in Turkey. MethOds: 
132 months sales data with segmented regression analysis for interrupted time 
series were used. International reference pricing of pharmaceuticals (RF), manda-
tory reimbursement dossier submission for new molecules, new indications and 
line extensions with medical and economic evaluations (MRDS), auditing for good 
manufacturing practice (GMP), family physician system (FP) and compulsory medi-
cal service for physicians (CMS) were selected as five major policies that may affect 
cost, demand and supply of pharmaceuticals. We analyzed possible breaks in trends 
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Objectives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of 
health including pharmaceutical sales by improving access to health services. 
Total pharmaceutical market reached US $ 8 billion in last 10 years. The objective 
of this study is to understand the differences in the impact of selected 5 policies 
on 5 top selling ATC1 groups in terms of cost sales (CS) in the respective peri-
ods. MethOds: 132 months sales data with segmented regression analysis for 
interrupted time series were used. International reference pricing of pharmaceu-
ticals (RF), mandatory reimbursement dossier submission for new molecules, new 
indications and line extensions with medical and economic evaluations (MRDS), 
auditing for good manufacturing practice (GMP), family physician system (FP) 
and compulsory medical service for physicians (CMS) were selected as five major 
policies that may affect cost, demand and supply of pharmaceuticals. We analyzed 
possible breaks in trends prior and after the implementation of 5 selected policies 
of the HTP. The Durbin-Watson d statistics of SPSS version 20.0 was used as a test 
for serial correlation of error terms. Shift in slope with p< 0.05 was considered 
as statistically significant. Results: There was an increasing trend for all ATC1 
groups prior the implementation of policies. The trends in systemic antienfec-
tives (J0), alimentary and metabolism (A0) and Respiratory system (R0) Central 
Nerveous System (N0) groups were negatively impacted from all policies except for 
RF. All policies impacted negatively the trend in cardiovascular system (C0) group. 
Implementation of RF had a significant positive impact on A0 and R0 group. Impact 
of RF was positive on C0 however it did not reach signifcance level. cOnclusiOns: 
Policy changes were very successful to control growth of top selling pharmaceuti-
cal groups while improving access to health. RF and CMS policies were the least 
effective cost containment measures
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Objectives: To compare the savings achieved by appraisal of the clinical and cost 
effectiveness of individual drugs by NICE’S Technology Appraisals for England & 
Wales with those due to price cuts under the Pharmaceutical Pricing Regulation 
Scheme 2000-2014. MethOds: Maximum and best estimates of savings attributable 
to the 512 technologies appraised and published by NICE to end 2013 with published 
reports of the PPRS. Published estimates of the cost of the Multiple Risk Sharing 
Scheme, the Cancer Drugs Fund and the End-of-Life criteria. Results: Savings 
attributable to NICE were relatively low. Few drugs were not recommended and of 
these, special schemes, funds and exceptions required by the governments of the 
day, reduced savings that might otherwise have resulted. The bulk of the savings 
due to NICE resulted from price cuts under Patient Access Schemes from 2009. 
Higher savings resulted from cross the board price cuts in the PPRS. cOnclusiOns: 
Health systems aiming to control pharmaceutical expenditure should consider both 
individual level appraisal of drugs as overall budget control of the branded prescrip-
tion drugs budget.
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Objectives: In 2003 Health Transformation Program and in 2006 Social Security 
Reform were launched in Turkey. At the end of the years 2009 and 2011 price cuts 
were done by the Government and between the years 2010-2012, there was a global 
budget implementation in Turkey. The top 100 medicines, annual average highest 
amount of sales of between 2008-2013, had one to four of the total pharmaceuti-
cal market value in 2013. We aimed to examine the status of original and generic 
medicines in the first 100 medicine’s and evaluate the effects of policy interven-
tions on these medicine sales. MethOds: While pharmaceutical sales data were 
obtained from the IMS Health-Turkey data base, prices and characteristics of medi-
cines were obtained from the Turkish Medicine and Medical Devices Agency data 
bases. Each group (original/generic medicines) was analyzed using TRAMO and 
SEATS method. Results: 78 medicines are original, 22 medicines are generic. In 
2009 compared to the previous year both generic and original medicine spending 
increased by respectively 16% and 20,9%. Between the years 2010-2012 compared 
to the previous year both generic and original medicines spending decreased by 
different ratios. In 2013 according to 2012, generic medicine spending decreased 
by 8.3% but original medicine spending increased by 7.9%. In 2013 total original 
medicine spending was 2888 million Turkish Liras (TL). This amount estimated to 
be 3050 million TL in 2014 and 3145 million TL in 2015. Generic medicines total 
spend was 501 million TL in 2013. This amount projected to be 510 million TL in 
2014 and 515 million TL in 2015. cOnclusiOns: Original medicines dominated the 
top 100 medicines. The total effect of the intervention is more negatively in generic 
medicines. At the end of 2013, it is understood that original medicines total amount 
have a tendency to increase.
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increase. We excluded “plasma-derived blood products” that has different pricing 
schemes for the cases they get an exchange rate related increase and also excluded 
the price corrections. Price increase reasons were grouped as defined in the current 
decree. We calculated mean percentage of price increases in overall and in original 
vs. generic, import vs. locally manufactured, products below and above 6.79 TL pack 
price (local definition of cheap products) and ATC1 level subgroups. Results: 606 
products and 274 molecules had price increase in 2013. The most frequent reasons 
for price increase were related critical product status (110 increases), increase in 
reference price (105 increases) and due to the rule of getting the highest reference 
for delisted or non-reimbursed products (89 increases). The average rate of price 
increases was 23.1%. 57% of the price increases were applied to imported products 
compared with 43% locally manufactured ones. Average rate of price increase in 
original and generic products were 24% and 21% respectively. Products with ex-
factory price above 6.79 TL had more price increase compared with cheap prod-
ucts. The highest rate of price increases were in ATC1 groups A and B (81 increases 
each) cOnclusiOns: With the pricing policy change in 2013, price increases were 
possible in Turkey for products from different groups.
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Objectives: In many countries there is an ongoing debate about pharmaceutical 
pricing. Especially in Germany there is common belief that pharmaceuticals are 
more expensive than in other countries. Payers are making use of this belief when 
negotiating prices with pharmaceutical companies. We wanted to know if there 
is scientific evidence for this conception. MethOds: We conducted a systematic 
literature review in order to identify price comparison studies comparing Germany 
with at least three other countries. We searched Pudmed and six other databases 
to identify relevant articles published between 1998 and today. Furthermore we 
developed a quality rating tool based on the approaches from Andersson (1993) and 
Danzon/Kim (1998). Results: Our review delivered 4.927 articles from which 28 met 
our inclusion criteria. Study quality was quite heterogeneous, ranging from 3 to 13 
points with an average score of 8.8 out of 15. Some studies use old data back from 
1992 and no study considers the recent changes in German legislation (AMNOG). 
In addition no study includes rebates and selection of compared pharmaceuticals 
is often arbitrary. Reviewed studies report German pharmaceutical prices slightly 
above international average. High quality studies (upper quartile, quality score: 
> 9) find German prices below international average, whereas low quality studies 
(lower quartile, quality score: < 7) find German prices above international aver-
age. cOnclusiOns: Results of the review suggest that there is a misconception of 
pharmaceutical pricing in Germany. Within a price comparison study any desired 
result can be achieved by deliberately choosing different approaches. At the end of 
the day payers and policy makers should stop comparing prices with other coun-
tries. Instead resources should better be spent on making value based reimbursment 
decisions in the respective health care setting.
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Objectives: Since January 2012, Turkish government started to implement a man-
datory general health insurance law. The Social Security Institution (SSI) coverage 
which has been 86% in 2012 was expected to be 100% after this reform instead has 
declined to 82% in 2013. On the other hand, as Turkish Green Card Program - a state 
social scheme to ensure the provision of health services for the poor - was abolished 
and transferred from Ministry of Health to SSI, approximately 9 million people have 
been subject to income audit in order to be classified as eligible to pay premiums 
themselves and non-eligible ones for which the state will pay the premiums. In this 
regard; this poster presents this transformation and gives its current status in terms 
of contribution to Universal Health Coverage in Turkey. MethOds: Publications of 
SSI, World Bank Reports and online articles are utilized. Results: The recent avail-
able data shows that 82% of the population is under the coverage of SSI. %2 of the 
population corresponds to the groups which are out of SSI coverage according to 
Law 5510, Article 60. Remaining population corresponds to 12 million people subject 
to income audit. Approximately 62% of those could not pass income audit and their 
premiums are paid by the state. cOnclusiOns: Since 2012 there are increasing 
number of people taking income audit and have the capacity to pay premiums. It is 
also noteworthy to state that there were 8,865,470 people under Green Card scheme 
whereas after the transfer of Green Card to SSI; 11,357,306 people applied for the 
income audit in 2012, this reached to 12,266,043 people at the beginning of 2014. 
Findings show that as Green Card Scheme brought under SSI, coverage has been 
made available to all eligible people in a systematic and just way thus contributed 
the extent of coverage in Turkey.
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Objectives: In early 2010, Greece was placed under International Supervision (EU, 
ECB and IMF), as a result of a growing public deficit and its non-sustainable state 
expenditure. At the time, the retail pharmaceutical market had a size of c. a. € 6.5 bn 
in retail prices (public pharmaceutical expenditure € 5.2 bn). Within that framework, 
prior and after the implementation of 5 selected policies of the HTP. The analysis 
was conducted for total imported pharmaceutical (IP) sales and total locally manu-
factured pharmaceutical (LMP) sales in the A0. The Durbin-Watson d statistics of 
SPSS version 20.0 was used as a test for serial correlation of error terms. Shift in 
slope with p< 0.05 was considered as statistically significant. Results: All policies 
effected the LMP sales more positively than IP sales except FP. However, the differ-
ence of impact was moderately positive for LMP sales, there was not any statisti-
cally significant change. cOnclusiOns: Policy changes may effect at differently 
direction and amount the cost sales of LMPs and IPs. Non significant effect of these 
policy changes may partly explained by limited oberservation time and by other 
market dynamics.
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Objectives: In 2003 Health Transformation Program and in 2006 Social Security 
Reform were launched in Turkey. At the end of the years 2009 and 2011 price cuts 
were done by the Government and between the years 2010-2012, there was a global 
budget implementation in Turkey. Health implications of these developments in the 
medicine market have not been analyzed in a comprehensive manner. The top 100 
medicines, annual average highest amount of sales of between 2008-2013, had one 
to four of the total pharmaceutical market value in 2013. In this study we aimed to 
determine these first 100 medicine’s, which have higher total sales amount, defining 
characteristics. MethOds: While pharmaceutical sales data were obtained from 
the IMS Health-Turkey data base, characteristics of medicines were obtained from 
the Turkish Medicine And Medical Devices Agency and the Social Security Agency 
data bases. Results: While 78 medicines are original, 22 medicines are generic. 
60 medicines are imported medicines, 40 medicines are manufactured medicines. 
19 medicines are biotechnological medicines and all of these biotechnological 
medicines are original and imported. 96 medicines covered by Social Security pay-
ments. Equivalent of 65 medicines are available (each equivalent group from 1-30, 
an average of 13 generics available). 19 medicines and 15 medicines are respectively 
systemic anti-infectives and antineoplastics and immunomodulating agents. In 
this study, the license holders of the medicines are 40 firms in total. 15 firms have a 
market share of 75% and the medicines which, have 77,7% portion of total amount, 
are created by multinational firms. cOnclusiOns: In the years which were the 
effects of reforms, price cuts and global budget implementation seen, the medicines 
which have higher total sales amount were mostly original, imported, covered by 
Social Security payments and created by multinational firms.
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Objectives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of health 
including pharmaceutical sales by improving access to health services. The objective 
of this study is to understand the differences in the impact of selected 5 policies 
on 5 top selling ATC1 groups in terms of unit sales (US) in the respective peri-
ods. MethOds: 132 months sales data with segmented regression analysis for 
interrupted time series were used. International reference pricing of pharmaceu-
ticals (RF), mandatory reimbursement dossier submission for new molecules, new 
indications and line extensions with medical and economic evaluations (MRDS), 
auditing for good manufacturing practice (GMP), family physician system (FP) and 
compulsory medical service for physicians (CMS) were selected as five major policies 
that may affect cost, demand and supply of pharmaceuticals. We analyzed possible 
breaks in trends prior and after the implementation of 5 selected policies of the 
HTP. The top 5 selling ATC1 groups were Systemic Antienfectives (J0), Cardiovascular 
System (C0), Alimentary and Metabolism (A0), Respiratory (R0) and Central Nerveous 
System (C0). The Durbin-Watson d statistics of SPSS version 20.0 was used as a test 
for serial correlation of error terms. Shift in slope with p< 0.05 was considered as 
statistically significant. Results: There was an increasing trend for all ATC1 groups 
prior the implementation of policies. The trends in J0 were negatively impacted from 
all policies except for RF. The C0 group was negatively impacted from all policies 
except for RF and CMS. The A0 group was positively impacted from all policies. The 
N0 was positively impacted from all policies except MRDS and FP. The R0 group was 
positively impacted from all policies except GMP and FP. cOnclusiOns: Policy 
changes were not sufficient to control unit growth of top selling pharmaceutical 
groups. The effect of other policies to control unit sales of these group should also 
be evaluated.
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Objectives: Turkey is using international reference pricing for the pharmaceu-
ticals. An update for Turkish pricing decree is published in April 2012 and price 
increases became more applicable due to various reasons. We analyzed price lists 
to identify pharmaceutical products that had any price increase in 2013 and defined 
causes in the decree MethOds: We reviewed weekly cumulative price lists pub-
lished in Turkish Medicines and Medical Device Institution and compared each list 
with the list published in the previous week to identify products that had price 
